Grace Therapeutics' IV Drug Offers Safer Profile for Deadly Brain Bleed

PRINCETON, NJ – April 14, 2026 – Grace Therapeutics is poised to capture the attention of the neurology community with promising new data for its investigational drug, GTx-104, an intravenous treatment for a life-threatening type of stroke. The company announced today that results from its pivotal STRIVE-ON Phase 3 safety trial have been accepted for presentation at the upcoming American Academy of Neurology (AAN) annual meeting in Chicago.

The findings suggest that GTx-104, a novel IV formulation of the long-standing drug nimodipine, offers a significantly safer profile and better patient outcomes compared to the current oral standard of care for aneurysmal subarachnoid hemorrhage (aSAH), a devastating brain bleed. This news arrives at a critical moment for the late-stage biopharma company, with a U.S. Food and Drug Administration (FDA) decision on the drug’s approval expected just days after the conference concludes.

A Safer Alternative for a Critical Condition

The STRIVE-ON trial was designed to address a critical and dangerous side effect of the current treatment: hypotension, or clinically significant low blood pressure. For patients recovering from a brain bleed, maintaining stable blood pressure is paramount to prevent further brain injury. The trial, which randomized 102 aSAH patients, successfully met its primary endpoint. Patients receiving GTx-104 via a standard peripheral IV line experienced a 19% reduction in episodes of drug-induced hypotension compared to those receiving oral nimodipine (28% versus 35%).

Beyond the primary safety goal, the data highlights a cascade of other benefits. A crucial measure of treatment efficacy is Relative Dose Intensity (RDI), which indicates how much of the prescribed medication a patient actually receives. A staggering 54% of patients on GTx-104 maintained an RDI of 95% or higher, ensuring consistent therapeutic levels. In stark contrast, only 8% of patients on the oral regimen achieved the same level of dosing consistency, a discrepancy that underscores the challenges of administering medication to critically ill individuals.

This improved dosing appears to translate directly into better patient recovery. The trial data revealed that 29% more patients treated with GTx-104 had favorable functional outcomes at 90 days post-treatment. Furthermore, the IV drug was associated with significant improvements in healthcare resource utilization, showing fewer intensive care unit (ICU) readmissions, fewer total days in the ICU, and fewer days requiring a ventilator. Adverse events were comparable between the two groups, with no new safety concerns identified for GTx-104.

Overcoming Decades-Old Treatment Hurdles

Aneurysmal subarachnoid hemorrhage is a relatively uncommon but particularly lethal form of stroke, accounting for about 5% of all stroke cases but a disproportionate share of mortality and long-term disability, often striking patients in their prime. For decades, the only FDA-approved drug to improve outcomes has been nimodipine, a calcium channel blocker intended to prevent secondary brain injury from vasospasm, a dangerous narrowing of the brain's blood vessels.

However, the standard oral formulation of nimodipine is fraught with challenges. Approximately half of aSAH patients are unconscious or have difficulty swallowing (dysphagia), necessitating administration through a nasogastric tube. This process is complex, prone to error, and carries risks. Furthermore, oral nimodipine has notoriously poor and variable bioavailability due to extensive metabolism in the liver and interactions with food, leading to unpredictable drug levels and the very hypotensive episodes the STRIVE-ON trial sought to mitigate.

"The current standard of care leaves much to be desired," commented a neurocritical care physician not involved in the study. "We struggle daily with the logistical nightmare of administering oral nimodipine to our sickest patients and managing its unpredictable effects on blood pressure. A reliable, well-tolerated IV formulation that ensures consistent dosing would be a game-changer for managing these complex cases."

Grace Therapeutics' GTx-104 was engineered specifically to solve these problems. It uses a unique nanoparticle technology to create an aqueous, injectable formulation of nimodipine, which is naturally insoluble. This allows for convenient and continuous administration through a standard peripheral IV line, bypassing the gut entirely and ensuring 100% bioavailability. This approach promises to eliminate dosing errors, reduce drug interactions, and provide the steady, predictable drug levels needed to protect the vulnerable brain.

The Strategic Path to Market

The positive Phase 3 results represent a major milestone for Grace Therapeutics, a company focused on developing therapies for rare and orphan diseases. GTx-104 has already been granted Orphan Drug Designation by the FDA, a status that provides incentives for development and, if approved, could grant seven years of marketing exclusivity in the United States.

The market for aSAH treatments is substantial and growing, projected to exceed $3 billion globally by 2035. With its clear advantages over the current standard of care and a lack of modern competitors, GTx-104 is well-positioned to capture a significant share of this market. The drug's potential is further protected by a robust intellectual property portfolio with over 40 granted and pending patents.

All eyes are now on the FDA. The agency accepted Grace Therapeutics' New Drug Application (NDA) for GTx-104 and has set a Prescription Drug User Fee Act (PDUFA) target action date of April 23, 2026. The timing could not be more dramatic, coming just two days after the company presents its compelling safety and efficacy data to thousands of neurologists at the AAN meeting. A positive decision would validate the company's drug delivery platform and mark its transition from a clinical-stage to a commercial-stage enterprise.

A Potential Paradigm Shift in Neurocritical Care

The impact of GTx-104 could extend far beyond its direct clinical benefits. By simplifying administration and reducing complications, the drug has the potential to streamline workflows in the neurocritical care unit. The reduction in ICU days and ventilator use observed in the STRIVE-ON trial points to significant pharmacoeconomic advantages, potentially lowering the immense financial burden aSAH places on patients and healthcare systems, where the average hospital cost per patient can exceed $220,000.

For nurses and physicians on the front lines, a therapy that eliminates the need for nasogastric tube administration and provides more predictable blood pressure control would reduce workload and allow them to focus on other critical aspects of patient care. This shift could represent a new paradigm in how aSAH is managed, moving from a reactive approach fraught with complications to a more proactive, controlled, and effective treatment strategy.

As Grace Therapeutics prepares for its presentation in Chicago and awaits its PDUFA date, the clinical and financial implications are profound. For the estimated 42,500 patients hospitalized with this devastating condition in the U.S. each year, the approval of GTx-104 could mark the most significant therapeutic advancement in a generation, offering a new standard of care with the promise of a safer path to recovery.